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Abstract
Objective: The molecular determinants of chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic
pulmonary arterial hypertension (iPAH) remain poorly understood. The receptor for advanced glycation endproducts (RAGE)
and its ligands: HMGB1 and S100A9 are involved in inflammatory disorders. We sought to investigate the role of the RAGE
axis in patients with CTEPH undergoing pulmonary endarterectomy (PEA), iPAH undergoing lung transplantation (LuTX).
The high pulmonary vascular resistance in CTEPH/iPAH results in pressure overload of the right ventricle. We compared
sRAGE measurements to that of patients with aortic valve stenosis (AVS) – pressure overload of the left ventricle.
Methods: We enrolled patients with CTEPH(26), iPAH(15), AVS(15) and volunteers(33). Immunohistochemistry with
antibodies to RAGE and HMGB1 was performed on PEA specimens and lung tissues. We employed enzyme-linked
immunosorbent assays to determine the concentrations of sRAGE, esRAGE, HMGB1 and S100A9 in serum of volunteers and
patients with CTEPH, iPAH, AVS before and after PEA, LuTX and aortic valve replacement (AVR).
Results: In endarterectomised tissues from patients with CTEPH RAGE and HMGB1 were identified in myofibroblasts (a-
SMA+vimentin+CD342), recanalizing vessel-like structures of distal myofibrotic tissues and endothelium of neointima. RAGE
was differentially expressed in prototypical Heath Edwards lesions in iPAH. We found significantly increased serum
concentrations of sRAGE, esRAGE and HMGB1 in CTEPH. In iPAH, sRAGE and esRAGE were significantly higher than in
controls. Serum concentrations of sRAGE were significantly elevated in iPAH(p,0.001) and CTEPH(p = 0.001) compared to
AVS. Serum sRAGE was significantly higher in iPAH compared to CTEPH(p = 0.042) and significantly reduced in AVS
compared to controls(p = 0.001). There were no significant differences in sRAGE serum concentrations before and after
surgical therapy for CTEPH, iPAH or AVS.
Conclusions: Our data suggest a role for the RAGE pathway in the pathophysiology of CTEPH and iPAH. PEA improves the
local control of disease but may not influence the systemic inflammatory mechanisms in CTEPH patients through the RAGE
pathway.
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Introduction
Pulmonary hypertension (PH) is currently defined as a
hemodynamic and pathophysiological condition with a mean
pulmonary artery pressure (PAPmean) of $25 mmHg at rest. The
European Society of Cardiology (ESC) and European Respiratory
Society (ERS) have classified these conditions into six groups.
Pulmonary arterial hypertension (PAH, group 1) can be the result
of a wide array of underlying diseases. The entity idiopathic
pulmonary arterial hypertension (iPAH, group 1.1) is used if no
underlying causative disease can be diagnosed. The increase in
pulmonary vascular resistance (PVR) is related to different
mechanisms, including vasoconstriction, proliferative and obstruc-
tive remodeling of the pulmonary vessel wall, inflammation and
thrombosis. The pathology of idiopathic pulmonary arterial
hypertension affects the small distal pulmonary arteries (PAs) with
a diameter less than 500 mm. Typical findings are hypertrophy of
the media, intimal proliferative and fibrotic changes, thickening of
the adventitia with perivascular inflammatory infiltrates, complex
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and thrombotic lesions [1]. A widely used pathological grading
system for pulmonary arterial changes in hypertensive pulmonary
vascular disease was published by Heath and Edwards in 1958
[2,3].
In stark contrast to iPAH, the characteristic pathology of
chronic thromboembolic pulmonary hypertension (CTEPH,
group 4) is remodeled central and proximal PAs. Organized
thrombotic formations build the luminal lining of the PA vessel
wall replacing physiological intima [1]. Endarterectomized tissues
from patients with CTEPH show vessel-like structures in material
obtained from distal areas, whereas proximal material is charac-
terized by lower cell density and sometimes the accumulation of
fresh thrombotic material [4].
As described above, iPAH and CTEPH are progressive diseases
of the distal (iPAH) and proximal (CTEPH) pulmonary vessels
leading to increased PVR and PAP. In the further course of these
diseases right ventricular dysfunction and ultimately right ventric-
ular failure is the leading cause of death. The prognosis of patients
is associated to right ventricular performance measures, such as
cardiac index and right atrial pressure. Right heart failure is
caused by pressure overload of the right ventricle. The increase in
wall stress leads to increased wall thickness by muscular
hypertrophy (increase in cell size by addition of sarcomeres).
Figure 1. RAGE and HMGB1 are expressed in myofibroblasts of endarterectomised chronic thromboembolic tissues of CTEPH
patients. One representative patient is shown (12 out of 15 patients (80%) displayed analogous staining patterns. Photograph showing the
macroscopic aspect of a representative PEA specimen (A). Scale bar: 6 cm. Immunohistochemical expression of RAGE (B, scale bar: 20 mm), HMGB1
(C), vimentin (D), alpha-smooth muscle actin (E) and CD34 (F) on adjacent tissue sections of the PEA specimen shown in (A). Scale bar: 40 mm. RAGE
receptor for advanced glycation endproducts, HMGB1 high mobility group box 1, CTEPH chronic thromboembolic pulmonary hypertension, PEA
pulmonary endarterectomy.
doi:10.1371/journal.pone.0106440.g001
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However, the chronic exposure to high RV pressures results in RV
dilation with a decrease in contractile forces. Pathological
inflammatory responses, oxidative stress and humoral responses
may further promote right heart failure [5]. The consequences of
RV failure are intractable ascites, renal impairment, malnutrition
and immobility [5,6]. Pharmacological therapy effective in PAH
did not prove to benefit patients with CTEPH [7]. Surgical
therapy for selected patients with CTEPH is pulmonary endar-
terectomy (PEA) [8]. Patients with CTEPH who are not amenable
to PEA and patients with iPAH are possible candidates for lung
transplantation (LuTX).
The overexpression of cytokine cascades may contribute to the
progression of heart failure - ‘‘cytokine hypothesis’’ for heart
failure [9]. Most of our knowledge on neurohormonal and
cytokine signaling, oxidative stress, inflammation, ischemia, and
cell death which may contribute to RV dilatation and failure is
inferred from research on left sided heart failure [10]. In patients
with chronic left-sided heart failure increased serum concentra-
tions of proinflammatory cytokines, such as tumor necrosis factor-
alpha (TNF-alpha), interleukin(IL)-1, and IL-6 correlate with
clinical and hemodynamic parameters of disease severity [11,12].
A S100 protein family member, S100A8/A9, has recently been
shown to activate cardiac fibroblasts to initiate angiotensin II-
induced hypertension cardiac injury [13]. Recently, increased left
ventricular hypertrophy (LVH) and diastolic dysfunction was
demonstrated in chronic uremic mice with transgenic expression
of the human S100/Calgranulin gene cluster containing the genes
and regulatory elements for S100A8, S100A9, and S100A12.
S100/calgranulin-mediated inflammation induced fibroblast
growth factor 23 (FGF23) in cardiac fibroblasts which in a
paracrine manner may mediate LVH and diastolic dysfunction
[14]. The role of biomarkers in pulmonary hypertension has been
reviewed recently [15].
The Receptor for Advanced Glycation Endproducts (RAGE), a
transmembrane receptor, is a member of the immunoglobulin
superfamily of receptors that interacts with different ligands. Since
its first characterization in 1992 where a high basal expression in
the lung was shown [16] a vast literature around this receptor, its
lung and vascular biology and pathology has evolved
[17,18,19,20]. First, advanced glycation endproducts (AGEs) were
identified as ligands [16]. Next, RAGE was identified as a cell
surface receptor for S100/Calgranulins amplifying chronic cellular
activation and tissue injury [21]. Further ligands were detected
later: high-mobility group box 1 (HMGB1) - also known as
amphoterin [22], Mac-1 and others. The current view that RAGE
- RAGE-ligand interaction augments pro-inflammatory pathways
is supported by the detection of RAGE and RAGE ligands in
tissues of various disease processes, such as arteriosclerosis [18],
diabetes [23], glomerulosclerosis [24], periodontal disease [25],
arthritis [26], transplantation [27] and other chronic inflammatory
disorders.
The extracellular soluble form of the receptor (sRAGE) can be
detected in serum of patients [28]. Proteolytic shedding of RAGE
by metalloproteinases has been described [29,30]. It functions to
bind ligands and thereby blocks interaction with and activation of
cell surface RAGE. An increased concentration of RAGE-ligands
leads to the formation of circulating sRAGE-ligand complexes. An
increasing occupation of sRAGE leads to lower concentration of
free sRAGE in serum and therefore directs to increased surface
RAGE-ligand interaction and possibly to a boost in inflammation.
Nevertheless, it is currently unknown if high plasma/serum
concentrations of sRAGE can be interpreted as protection against
chronic inflammation or correlated with high levels of ongoing
inflammation [29]. Currently available tools to measure sRAGE
don’t separate between sRAGE-ligand complexes and free
sRAGE. There is an alternative splice variant of the RAGE gene,
called endogenous secretory RAGE (esRAGE) that is actively
secreted. [31,32]. In conclusion, neither the function nor the
source of sRAGE in human physiology is known. Expression
profiling for esRAGE in multiple human organs and RAGE in
human thymus has recently been performed [33,34]. Plasma/
serum concentrations of sRAGE in diabetes mellitus type 2 and
coronary artery disease have been studied with conflicting findings
[35,36].
The RAGE ligand HMGB1 is a non-histone chromosomal
protein which functions as a DNA chaperone. The molecule is
composed of two homologous DNA binding domains and an
acidic tail. Different binding domains for its receptors: RAGE,
Toll-like receptor 4 (TLR4) and a p53 transactivation domain
have been identified. Once HMGB1 is released from the cell it acts
as a signaling molecule, namely a damage-associated molecular
pattern molecule (DAMP) [37,38].
There is a myriad of studies (mostly animal models) implicating
a role for RAGE and its ligands in the pathogenesis of vascular
disease. Most of these studies have investigated the systemic
vessels. Studies in mice with diabetic atherosclerosis showed that
Table 1. The basic characteristics of patients with CTEPH and controls (healthy volunteers) are listed.
CTEPH (n=26) Controls (n =33) p value
Age in years 51.9 (56.2) 614.7 (2.9), [31–75] 54.2 (54.0) 615.2 (2.6), [30–83] 0.828
F:M ratio n (%) 9:17 (34.6:65.4) 12:21 (36.4:63.6) 0.985
PAPmean [mmHg] 52.9 (52.0) 614.6 (2.9), [32–90]
PVR [dynes?s21?cm25] 787.2 (757.0) 6386.6 (75.8), [281–1646]
CI [l/min/m2] 4.4 (4.5) 60.99 (0.19), [2.2–5.4]
sRAGE [pg/ml] 467.2 (331.8) 6370.4 (72.6), [105.0–1461.6] 198.6 (142.8) 6162.9 (28.3), [6.4–807.6] 0.001
esRAGE [pg/ml] 703.7 (610.8) 6309.3 (63.1), [170.0–1370.0] 414.5 (378.8) 6177.1 (31.8), [180.0–790.0] ,0.001
S100A9 [mg/ml] 2.1 (0.7) 63.9 (0.8), [0.3–18.2] 0.7 (0.6) 60.5 (0.09), [0.2–2.1] 0.064
HMGB1 [pg/ml] 1141.1 (865.8) 6865.6 (173.1), [226.5–3584.8] 464.3 (411.3) 6371.1 (66.6), [0–1818.4] 0.001
Reported is mean (median) 6 standard deviation (standard error mean), [range].
CTEPH chronic thromboembolic pulmonary hypertension, n number of patients, F:M ratio female to male ratio, PAPmean mean pulmonary artery pressure, PVR pulmonary
vascular resistance; CI cardiac index, sRAGE soluble receptor for advanced glycation endproducts, esRAGE endogenous secretory receptor for advanced glycation
endproducts, S100A9 member of S100 family of Ca+ binding proteins, HMGB1 high mobility group box1.
doi:10.1371/journal.pone.0106440.t001
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treatment with murine sRAGE suppressed the development of
accelerated diabetic atherosclerosis in a dose-dependent manner
[39,40].
The hypothesis that RAGE could be a key player in pulmonary
hypertension was inferred from evidenced based reviews of the
scientific literature [41]. The RAGE – RAGE-ligand axis might
drive the inflammatory changes in the walls of pulmonary vessels
(macro- and microangiopathy) in a similar way as has been shown
for the systemic vasculature. A role for RAGE in human
pulmonary artery smooth muscle cells (hPASMCs) of patients
with idiopathic pulmonary arterial hypertension (iPAH) and in
in vivo animal models of monocrotaline- and Sugen-induced PAH
was recently described [42]. Further, HMGB1 was shown to
contribute to PH via a Toll-like receptor 4 (TLR4)-dependent
mechanism in a murine model of chronic hypoxia (CH)-induced
PH [43].
In a mouse model of hypobaric hypoxia (10% O2)-induced PH
treatment with sRAGE was protective against increases in RV
pressure but did not affect distal pulmonary vascular remodeling.
In vitro the administration of sRAGE modulated vasoreactivity of
intralobar pulmonary arteries from hypobaric hypoxic mice and
further enhanced hypoxia-induced proliferation of Chinese
hamster lung fibroblasts [44].
We sought to investigate a possible role of RAGE and HMGB1
in diseased main to segmental pulmonary arteries of patients with
CTEPH undergoing PEA and small PAs (,500 mm) in iPAH
patients undergoing lung transplantation. Moreover, we hypoth-
esized that systemic inflammatory changes pertaining to RAGE
and RAGE ligands (HMGB1, S100A9) can be measured in
patients with CTEPH and iPAH. We compared systemic
measurements of CTEPH and iPAH patients to those of patients
with aortic valve stenosis (AVS). We aimed to filter out changes
specific to PH, a disease characterized by pressure overload of the
right ventricle in comparison to a disease that inflicts pressure
overload on the left ventricle, such as AVS. Lastly, we sought to
investigate the effects of surgical therapy, such as PEA, LuTX and
AVR on systemic inflammation.
Materials and Methods
Ethics Statement
Ethical approval was obtained from the Medical University
Vienna review board on human research. Written informed
consent was obtained from all patients and volunteers participating
in this study.
Definitions
PH is defined as an increase in mean pulmonary arterial
pressure (PAP) $25 mmHg at rest as assessed by right heart
catheterization [1]. CTEPH is defined by the following observa-
tions after $3 months of effective anticoagulation: (1) mean PAP$
25 mmHg with a pulmonary capillary wedge pressure (PCWP) #
15 mmHg; and (2) at least one (segmental) perfusion defect
detected by lung scanning, multi-detector computed tomography
angiography or pulmonary angiography [45].
iPAH is a clinical condition characterized by the presence of
precapillary PH in the absence of other causes of precapillary PH
[1].
Figure 2. RAGE and HMGB1 expression on endothelial cells of regular PA and endarterectomised tissues. Representative examples of
12 examined patients are shown. Immunohistochemical analysis of regular main pulmonary artery with RAGE expression on endothelium and
smooth muscle cells is shown (A). Scale bar: 40 mm. RAGE expressing endothelial cells in vessel-like structures recanalizing the matrix of distal PEA
material (B). Endothelial cells expressing RAGE in proximal PEA tissue (arrows point at neointima, C) and HMGB1 (* in recanalizing vessel-like
structures, D) in distal PEA specimen are displayed. Scale bar: 20 mm. RAGE receptor for advanced glycation endproducts, HMGB1 high mobility group
box 1, PA pulmonary artery, PEA pulmonary endarterectomy.
doi:10.1371/journal.pone.0106440.g002
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Subjects
We prospectively enrolled 26 patients with CTEPH undergoing
PEA, 15 patients with iPAH undergoing lung transplantation, 15
patients with severe aortic stenosis undergoing aortic valve
replacement and 33 healthy control subjects between 2010 and
2014. PEA and LuTX surgery were carried out at the department
of thoracic surgery, Medical University Vienna, aortic valve
replacement (AVR) surgery at the department of cardiac surgery,
University Debrecen. The diagnosis of CTEPH and indication for
PEA surgery was established by teams of specialists in the diagnosis
and treatment of patients with pulmonary hypertension, CTEPH
and lung transplantation in every case. All patients with CTEPH
were classified to have type 2 disease, intimal thickening and
fibrosis proximal to the segmental arteries, according to the
intraoperative classification system [8]. The diagnosis of AVS and
indication for AVR surgery was established by teams of specialists
in cardiology and cardiac surgery in every case. Patient
characteristics are given in Tables 1–3.
None of the control subjects studied had any evidence or
suspicion of any form of pulmonary hypertension, autoimmune
disease, malignancies or infectious conditions at the time of entry
into this study. None of the volunteers received anticoagulants,
Figure 3. RAGE expression in pulmonary vascular changes of patients with iPAH. Representative examples of immunohistochemical
analyses of pathognomonic lesions in lung of patients with iPAH according to the modified Heath Edwards classification in PA vessels smaller than
500 mm in diameter are shown (3 patients per every Heath Edwards group were analysed). RAGE expression in (A) a morphologically regular small PA
- stage 0 and (B) a stage 1 histological change in lung of a patient operated for pneumothorax (COPD 0, centriacinar emphysematous changes). RAGE
expression in characteristic stage 2 changes in a lung of a patient with iPAH (C). Scale bar in A, B and C: 80 mm. Adjacent sections of H&E (D) and EvG
(E) and RAGE staining (F) for stage 3 changes in iPAH. Scale bar in D, E and F: 40 mm. Stage 4, angiomatoid (insert with adjacent H&E section, G), and
stage 5, plexiform (H) PA vessel changes are shown. Scale bar in G and H: 80 mm. iPAH idiopathic pulmonary arterial hypertension, PA pulmonary
artery, RAGE receptor for advanced glycation endproducts, COPD chronic obstructive pulmonary disease, H&E hematoxylin and eosin staining, EvG
Elastica van Gieson staining.
doi:10.1371/journal.pone.0106440.g003
Figure 4. Serum concentrations of RAGE axis molecules in patients with CTEPH. Box plot analysis of serum concentrations of sRAGE (A),
esRAGE (B), S100A9 (C) and HMGB1 (D) in patients with CTEPH (n= 26) and controls (n = 33). Independent Student’s t-test was used to compare
groups. RAGE receptor for advanced glycation endproducts, sRAGE soluble RAGE, esRAGE endogenous secretory RAGE, S100A9 member of S100
family of Ca+ binding proteins, HMGB1 high mobility group box1, CTEPH chronic thromboembolic pulmonary hypertension.
doi:10.1371/journal.pone.0106440.g004
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Figure 5. Serum concentrations of RAGE axis molecules in patients with iPAH. Box plot analysis of serum concentrations of sRAGE (A),
esRAGE (B), S100A9 (C) and HMGB1 (D) in patients with iPAH (n= 8) and controls (n = 11). Independent Student’s t-test was used to compare groups.
RAGE receptor for advanced glycation endproducts, sRAGE soluble RAGE, esRAGE endogenous secretory RAGE, S100A9 member of S100 family of Ca+
binding proteins, HMGB1 high mobility group box1, iPAH idiopathic pulmonary arterial hypertension.
doi:10.1371/journal.pone.0106440.g005
Table 2. The basic characteristics of patients with iPAH and controls (healthy volunteers) are listed.
iPAH (n=8) Controls (n =11) p value
Age in years 36.6 (37.4) 69.9 (3.5), [21–50] 36. 4(33.0) 612.3 (3.7), [22–62] 0.963
F:M ratio n (%) 8:0 (100:0) 10:1 (90.9:9.1) 0.381
PAPmean [mmHg] 54.5 (57.5) 620.0 (10.0), [28–75]
PVR [dynes?s21?cm25] 1425.0 (1505.0) 6582.1 (291.0), [706–1984]
CI [l/min/m2] 3.7 (3.8) 60.4 (0.1)
sRAGE [pg/ml] 743.7 (401.9) 6672.9 (254.3), [123.9–1861.7] 195.5 (130.8) 6130.9 (39.5), [51.0–441.1] 0.017
esRAGE [pg/ml] 1391.1 (972.9) 61073.2 (379.4), [280.0–3110.0] 423.2 (399.4) 6197.1 (59.4), [210.0–750.0] 0.009
S100A9 [mg/ml] 1.4 (0.8) 61.7 (0.6), [0.5–5.6] 0.9 (0.7) 60.5 (0.1), [0.4–2.1] 0.374
HMGB1 [pg/ml] 1419.4 (845.2) 61614 (610.1), [381.5–5020.9] 415.1 (410.6) 6207.0 (65.5), [80.6–833.3] 0.067
Reported is mean (median) 6 standard deviation (standard error mean), [range].
iPAH idiopathic pulmonary arterial hypertension, n number of patients, F:M ratio female to male ratio, PAPmean mean pulmonary artery pressure, PVR pulmonary vascular
resistance; CI cardiac index, sRAGE soluble receptor for advanced glycation endproducts, esRAGE endogenous secretory receptor for advanced glycation endproducts,
S100A9 member of S100 family of Ca+ binding proteins, HMGB1 high mobility group box1.
doi:10.1371/journal.pone.0106440.t002
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prostaglandins, immunosuppressant therapy or any other type of
prescribed medication.
Human tissue and serum sample collection
Fresh tissues (PEA specimens, pulmonary arteries and lung
tissues) were harvested at the time of PEA (from patients with
CTEPH), lung transplantation (from patients with iPAH, CF and
COPD) and video-assisted thoracoscopic surgery for recurrent
primary spontaneous pneumothorax (otherwise healthy individu-
als). Histological diagnoses and classification of iPAH in this study
was routinely performed at the clinical institute of pathology at the
Medical University Vienna.
Serum samples were centrifuged within 60 minutes of collection
and stored at 280uC until analysis. In CTEPH the first results
from serum analysis were obtained in 26 patients compared to 33
controls (table 1). For the next step we collected serum samples 10
days after (12 patients) and 1 year after PEA (9 different patients;
summarized in table 3). Similarly, in iPAH the first result was
obtained in serum of 8 patients compared to controls (table 2). In
the next step we collected serum samples of 7 different patients
with iPAH before and 3 weeks after lung transplantation (table 3).
A total of 15 patients with iPAH were included in the study. Age-
and sex-matched controls used for subset analysis are part of the
whole control pool. Serum samples were collected before and 10
days after AVR (table 3). All postoperatively collected serum
samples stem from patients with an uneventful postoperative
course.
Figure 6. Serum concentrations of sRAGE in patients before and after surgery for CTEPH, iPAH and AVS. Box plot analysis of serum
concentrations of sRAGE in patients with CTEPH (n= 20), iPAH (n = 7), AVS (n = 15) and controls (n = 28, A). Box plot analysis of sRAGE in serum of
patients with CTEPH before and after PEA, in patients with iPAH before and after double lung transplantation and in patients with AVS before and
after AVR (B). Box plot analysis of serum concentrations of sRAGE in patients with CTEPH and iPAH (C). One-way ANOVA was used to compare groups.
Post hoc comparisons were computed with the Tukey correction. RAGE receptor for advanced glycation endproducts, sRAGE soluble RAGE, CTEPH
chronic thromboembolic pulmonary hypertension, PEA pulmonary endarterectomy, iPAH idiopathic pulmonary arterial hypertension, AVS aortic valve
stenosis, AVR aortic valve replacement.
doi:10.1371/journal.pone.0106440.g006
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Immunohistochemistry
Formaldehyde-fixed and paraffin-embedded human PEA spec-
imens, lung tissues and PAs were prepared according to routine
protocols of the clinical institute of pathology. Briefly, sections
2 mm in thickness, were baked for 1 hour at 55uC, deparaffinized
in three xylenes and rehydrated in ethanol as follows: 26100%,
1695%, 1690%, and 1670%, followed by PBS. Antigen retrieval
was performed by boiling slides at 600 watt (365 min) in a
microwave oven using citrate buffer at pH 6.0 (Target Retrieval
Solution, Dako, USA). Endogenous peroxidase activity was
blocked by applying hydrogen peroxide 0.3%. Sections were
incubated with 2% bovine serum albumin or blocking serum of the
same species as the biotinylated secondary antibody to deplete
unspecific protein-protein interactions. Sections were stained using
affinity-purified polyclonal goat anti-human RAGE IgG (R&D
Systems, Minneapolis, MN, USA) or monoclonal mouse anti-
human HMGB1 IgG2b (R&D Systems) and biotinylated anti-goat
IgG or anti-mouse IgG secondary antibodies (Vector Laboratories,
Burlingame, CA, USA). Immunoreactivity was amplified using
biotin-avidin peroxidase conjugates (Vectastain ABC kit, Vector
Laboratories). 3,39-diaminobenzidine was used as chromogen
(DAB Peroxidase substrate kit, Vector Laboratories). Counter-
staining was performed using Mayer’s hematoxylin. Slides were
dehydrated with ethanol: 1695% for 1 min, 16100% for 6 min
and cleared in n-Butanol before mounting (Pertex Mounting
Media, Leica Microsystems, Germany).
Immunohistochemistry for representative markers of hemato-
poietic precursor cells CD34, the intermediate filament vimentin
and smooth muscle a-actin (a-SMA) were performed on adjacent
sections of PEA specimens using the automated Ventana
Benchmark platform (Ventana Medical Systems, Tucson, AZ,
USA) according to routine protocols of the clinical institute of
pathology. Sections were stained with monoclonal mouse anti-
human a-SMA (Clone1A4; Dako, Denmark, Europe), monoclonal
mouse anti-human CD34 IgG1 (Clone QBEnd/10; Novocastra,
Leica Biosystems Newcastle, UK, Europe) and monoclonal rabbit
anti-human vimentin IgG (clone SP20; Thermo Fisher Scientific,
Fremont, USA). Heat pre-treatment was conducted in Ultra cell
conditioner number 1 buffer (Ultra CC1; pH 6). Color was
developed with Ultraview Universal Detection DAB-kit (Ventana
Medical Systems). Immunohistochemical staining for RAGE and
HMGB1 was reproduced with the described automated system.
Omission of primary antibody served as negative control.
Hematoxylin and eosin (H&E) staining was performed according
to routine protocols. Analysis and image documentation was done
Table 3. Clinical characteristics of patients with CTEPH before and after PEA, iPAH before and LuTX, AVS before and after AVR.
CTEPH (n=20) Before PEA After PEA p value
sRAGE [pg/ml] 743.29 (582.90) 6117.62 (26.98), [125.33–2085.55] 688.70 (609.14) 6396.60 (88.68), [141.84–1712.88] 0.724
Age in years 60.24 (63.99) 612.99 (2.91), [31–78]
F:M ratio n (%) 5:15
PAPmean [mmHg] 53.53 (53.00) 615.26 (3.50), [28.00–90.00] 27.42 (27.00) 66.05 (1.39), [18.00–39.00] ,0.001
PVR [dynes?s21?cm25] 701.27 (690.00) 6277.95 (67.41), [329.00–1257.00] 265.37 (248.00) 6117.62 (26.98), [88.00–539.00] ,0.001
CI [l/min/m2] 1.92 (2.12) 61.13 (0.25), [0.00–4.20] 2.08 (2.20) 61.42 (0.33), [0.00–3.86] 0.542
iPAH (n = 7) Before LuTX After LuTX
sRAGE [pg/ml] 1216.05 (1315.27) 6564.95 (213.53), [326.47–1835.31] 772.83 (519.91) 6694.85 (262.63), [125.95–1880.66] 0.168
Age in years 33.43 (34.00) 66.23 (2.35), [21–40]
F:M ratio n (%) 5:2
PAPmean [mmHg] 82.57 (77.00) 617.63 (6.66), [54.00–103.00] 22.57 (22.00) 63.41 (1.29), [19.00–29.00] ,0.001
PVR [dynes?s21?cm25] 1733.60 (1800.00) 6200.71 (89.76), [1452.00–1984.00]
CI [l/min/m2] 1.99 (2.00) 60.27 (0.11), [1.70–2.30] 4.27 (4.50) 60.59 (0.34), [3.60–4.70] 0.074
AVS (n = 15) Before AVR After AVR
sRAGE [pg/ml] 260.26 (216.04) 6171.40 (44.26), [104.01–808.26] 274.45 (221.26) 6199.24 (51.44), [83.91–874.58] 0.804
Age in years 65.23 (64.50) 610.31 (2.66), [44–86]
F:M ratio n (%) 6:9
PAPmean [mmHg] 18.87 (19.00) 64.94 (1.28), [9.00–28.00)
Mean grad 47.47 (43.00) 616.22 (4.19), [29.00–84.00]
Vmax m/s 4.47 (4.30) 60.73 (0.19), [3.80–6.20]
AVA 0.76 (0.80) 60.21 (0.06), [0.30–1.00]
Controls (n = 28)
sRAGE [pg/ml] 567.80 (446.78) 6329.09 (62.19) [122.48–1355.13]
Age in years 58.50 (62.00) 620.72 (3.92) [30–91]
F:M ratio n (%) 12:16
Reported is mean (median) 6 standard deviation (standard error mean), [range].
CTEPH chronic thromboembolic pulmonary hypertension¸ PEA pulmonary endarterectomy, iPAH idiopathic pulmonary arterial hypertension, LuTX double lung
transplantation, AVS aortic valve stenosis; AVR aortic valve replacement, Mean grad mean transvalvular pressure gradient, Vmax maximum aortic stenosis jet velocity,
AVA aortic valve area, F:M ratio female to male ratio, PAPmean mean pulmonary artery pressure, PVR pulmonary vascular resistance; CI cardiac index, sRAGE soluble
receptor for advanced glycation endproducts, n number of patients.
doi:10.1371/journal.pone.0106440.t003
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with Axio Imager 2 microscope and AxioVision software (Carl
Zeiss International, Germany).
Grading of pulmonary vascular lesions
Specimens of explanted lungs from patients undergoing lung
transplantation for iPAH were harvested at the time of transplan-
tation. Sections were stained for hematoxylin and eosin (H&E) and
Elastica van Gieson (EvG) to visualize elastin and analyzed
according to a modified Heath Edwards classification system
changes in small pulmonary arteries. Grade 1 is characterized by
extension of muscle cells into distal arterioles and thickening of the
media of muscular arteries. Grade 2 is defined as hypertrophy of
the media with intimal proliferation in small muscular arteries.
Grade 3 shows progressive fibrous vascular occlusion and
concentric intimal fibrosis. Grade 4 is characterized by progressive
arterial dilatation with plexiform lesions, grade 5 by chronic
dilatation with fibrosis of intima and media, prominent plexiform
and angiomatoid lesions and pulmonary hemosiderosis.
Evaluation of immunoreactivity
Analysis of immunoreactivity was performed by two observers
blinded to the type of antibodies used for staining. Two to four
slides per patient were assessed. We assigned a score from 0 to 3 to
assess staining intensity for RAGE or HMGB1 cytoplasmic or
nuclear expression in PEA specimens, PA and small PA in lungs of
patients with pneumothorax, iPAH and COPD (0, no staining; 1,
weak; 2, moderate; 3, strong).
Detection of serum proteins
To test the hypothesis that RAGE and HMGB1 are involved
systemically in patients with pulmonary hypertension, we
employed enzyme-linked immunosorbent assays (ELISA) for the
detection of sRAGE, esRAGE, S100A9 and HMGB1 in serum of
patients with CTEPH, iPAH, AVS and healthy volunteers. All
ELISA tests were performed according to the manufacturers’
instructions: sRAGE (RAGE Duoset Elisa, RnD Systems, Minne-
apolis, MN, USA), esRAGE (B-Bridge International Inc., CA,
USA), S100A9 (Abnova, Taipei City, Taiwan) and HMGB1 (IBL
International GmbH, Hamburg, Germany). Researchers perform-
ing the assays and data analyses were blinded to the groups
associated with each sample.
Statistical methods
We performed an observational study with longitudinal (cohort
study: measurements before and after PEA, LuTX and AVR) and
cross-sectional design (e.g. serum sRAGE concentration in
CTEPH/iPAH compared to controls). Statistical analysis of data
was performed using SPSS software (version 20; IBM SPSS Inc.,
IL, USA). Data were reported as mean (median) 6 standard
deviation (and standard error mean) in tables and as mean 6
standard error mean in the abstract and results section. The
concentrations of proteins in serum of patients with CTEPH,
iPAH and AVS were compared to those of healthy volunteers
using independent Student’s t test or One-way ANOVA for
normal (Gaussian) distributions. Kruskal-Wallis rank test or
Mann-Whitney U test was used to evaluate non-normal distribu-
tions. Post hoc comparisons were computed with the Tukey
correction. The paired t-test was applied to before and after
measurements made on the same group of subjects, such as
sRAGE serum concentrations before and after PEA. Pearson’s x2
test for independence was used for analysis of categorical data,
such as sex differences. Spearman’s rank correlation test was used
to assess possible correlations of sRAGE and mean pulmonary
artery pressure. The level of statistical significance was set at ,
0.05 (two-tailed p-values).
Results
Expression of RAGE and HMGB1 in endarterectomized
tissue from CTEPH patients, regular PA morphology and
diseased small PAs in patients with iPAH
Expression of RAGE and HMGB1 in endarterectomized
tissues of patients with CTEPH. Diseased central, lobar and
segmental PAs in CTEPH patients undergoing PEA showed
thromboembolic material incorporated into the remodeled vessel
wall in the form of intimal thickening and formation of neointima.
The macroscopic aspect of a representative PEA specimen is
shown (Fig. 1A). Hematoxylin and eosin stained sections revealed
the prototypic morphology of fibroblasts/fibrocytes forming a
honeycomb-like network. To test the hypothesis that RAGE and
HMGB1 are involved in CTEPH, we employed immunohisto-
chemical analysis for the detection of RAGE and HMGB1 in PEA
specimens (fig. 1B+C). We found cytoplasmic staining for RAGE
and cytoplasmic and nuclear staining for HMGB1 in the majority
of patients examined (12 out of 15 patients, 80.0%). The
specimens of the same 12 patients stained for RAGE and
HMGB1. Nuclear staining for RAGE was not detected. In
positive specimens 70.964.2% of cells showed RAGE and
72.864.6% showed HMGB1 expression.
Identification of RAGE and HMGB1 expressing cells as
myofibroblasts. We performed analysis on adjacent sections to
further characterize RAGE+ and HMGB1+ cells in endarterecto-
mized tissues. We found that RAGE+ and HMGB1+ cells were
also expressing the intermediate filament vimentin and a-SMA.
CD34, a representative marker of hematopoietic precursor cells,
did not correlate with the expression pattern seen for RAGE+
HMGB1+ vimentin+ a-SMA+ cells. The expression of CD34
expressing cells can rather be described as sporadic nests in 30.0%
of tissues, a homogeneous distribution throughout any of the
specimens was not found (fig. 1).
RAGE and HMGB1 expression in neointima and small
vessel-like structures recanalizing distal ‘‘myofibrotic’’
clots. RAGE cytoplasmic staining was detected in endothelium
of the intimal vessel wall (100% of endothelial cells) and smooth
muscle cells of the media (64.8%) of regular main PAs. Vessel-like
structures in distal areas of endarterectomized tissues showed
RAGE and HMGB1 expression. Neointima (cell layer outlining
the luminal surface) covering the organized thromboembolic
material of diseased PAs displayed RAGE and HMGB1 expres-
sion (fig. 2). These staining patterns were analogous in all 12
patients examined.
Differentiated expression of RAGE in small PAs (,500 mm
in diameter). In order to quantify the expression of RAGE in
PA changes prototypical for PH we employed immunohistochem-
ical analysis for the detection of RAGE in lung tissue specimens of
patients with iPAH, COPD and pneumothorax (fig. 3). Prototyp-
ical Heath Edwards lesions were identified by H&E and EvG
staining. We investigated lesions from three patients for every
Heath Edwards group. Cytoplasmic RAGE expression was found
in endothelium of Heath Edwards stages 0–5. The staining
intensity in endothelial cells was as follows: stages 0–1: weak, stages
2–5: moderate. In smooth muscle cells of small muscular PAs
RAGE was detectable with the following staining intensities: stages
0–1 (absent to weak), stages 2–5 (weak to moderate). Nuclear
staining for RAGE was not detected. The described staining
patterns and intensities were uniform throughout all patients
examined.
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Systemic measurements: Concentration of sRAGE,
esRAGE and RAGE ligands: HMGB1 and S100A9 in serum
of patients with PH and AVS
Increased levels of sRAGE, esRAGE and HMGB1 in
serum of patients with CTEPH. Basic demographic and
hemodynamic data of patients with CTEPH and volunteers are
detailed in table 1. There was no statistically significant difference
in age (p = 0.828) and sex (p = 0.985) between patients with
CTEPH (n=26) and controls (n = 33). We found significantly
elevated serum concentrations of sRAGE in patients with CTEPH
compared to controls (sRAGE [pg/ml] 467.2672.6
vs.198.6628.3; p = 0.001). Similarly, serum concentrations of the
splice variant esRAGE were significantly higher than those of
controls (esRAGE [pg/ml] 703.7663.1 vs. 414.5631.8; p,
0.001). The RAGE ligand S100A9 was not significantly different
(S100A9 [mg/ml] 2.160.8 vs. 0.760.09; p = 0.064) whereas
HMGB1 was significantly elevated in serum of patients with
CTEPH (HMGB1 [pg/ml] 1141.16173.1 vs. 464.3666.6;
p = 0.001; fig. 4, table 1). There was no significant correlation of
serum sRAGE concentrations with mean pulmonary artery
pressure in patients with CTEPH (correlation coefficient 0.116,
p = 0.646).
Higher concentrations of sRAGE and esRAGE, but not
HMGB1 and S100A9 in patients with iPAH. Basic demo-
graphic and hemodynamic data of patients with iPAH and
volunteers are detailed in table 2. There was no significant
difference in age (p= 0.963) and sex (p = 0.381) between patients
with iPAH and controls. We found significantly elevated
concentrations of sRAGE and esRAGE in patients with iPAH
(sRAGE [pg/ml]: 743.76254.3 vs. 195.5639.5; p = 0.017;
esRAGE [pg/ml] 1391.16379.4 vs. 423.2659.4; p = 0.009).
Conversely, the measured RAGE ligands: serum S100A9 and
HMGB1 in patients with iPAH did not differ from controls
(S100A9 [mg/ml] 1.460.6 vs. 0.960.1, p = 0.374; and HMGB1
[pg/ml] 1419.46610.1 vs. 415.1665.5, p = 0.067; fig. 5, table 2).
There was no significant correlation of serum sRAGE concentra-
tions with mean pulmonary artery pressure in patients with iPAH
(correlation coefficient 20.144, p= 0.734).
Serum concentrations of sRAGE were significantly higher
in iPAH and CTEPH (iPAH.CTEPH) in relation to reduced
concentrations in AVS patients. We wanted to test the
hypothesis that sRAGE serum concentrations are only elevated
in diseases of the pulmonary circulation leading to pressure
overload of the right ventricle compared to disease leading to
pressure overload of the left ventricle, such as AVS. Basic
demographic and hemodynamic data of patients with CTEPH
undergoing PEA, iPAH undergoing lung transplantation, AVS
undergoing AVR and volunteers are detailed in table 3.
ANOVA analysis of sRAGE concentrations from patients with
CTEPH, iPAH, AVS and healthy volunteers revealed significant
differences (p,0.001). Post-hoc comparisons showed significantly
higher serum concentrations of sRAGE in patients with iPAH (p,
0.001) and CTEPH (p= 0.001) compared to AVS (fig. 6). Further
post-hoc comparisons revealed no difference in serum sRAGE
concentration between patients with CTEPH and iPAH
(p= 0.066). Separate analysis of patients with CTEPH and iPAH
showed significantly higher serum sRAGE concentrations in
patients with iPAH compared to CTEPH (independent samples
t-test: p = 0.042). Serum sRAGE concentrations were significantly
reduced in patients with AVS compared to controls (p = 0.001).
Influence of surgical therapy on serum sRAGE
concentrations. There were no significant differences in
sRAGE serum concentrations before and after surgical therapy
for CTEPH, iPAH or AVS. Basic demographic and hemodynamic
data are detailed in table 3. The results were as follows: CTEPH
patients before and after PEA (sRAGE [pg/ml] 743.29626.98 vs.
688.70688.68, p = 0.724), iPAH patients before and after lung
transplantation (sRAGE [pg/ml] 1216.06213.5 vs. 772.86262.6,
p = 0.168) and patients with AVS before and after AVR (sRAGE
[pg/ml] 260.2644.2 vs. 274.4651.4, p = 0.804; table 3, fig. 6).
For patients undergoing PEA, early (10 days after PEA) and late
(one year after PEA) postoperative serum samples were available:
There was no difference in sRAGE concentrations when
measurements were stratified between early and late: before and
early after PEA (n = 12): (sRAGE [pg/ml]: 692.86168.3 vs.
534.1659.8, p = 0.451; before and one year after PEA (n= 9):
804.96214.7 vs. 877.66167.1, p= 0.767; in comparison to all
patients (n = 21) together: as above: p = 0.724.
Discussion
The results of this study describe for the first time the expression
of RAGE and HMGB1 in myofibroblasts of patients with
CTEPH. Prior studies have shown the majority of cells in
endarterectomised tissues from patients with CTEPH to be
myofibroblasts [46,47]. The presence of multipotent mesenchymal
progenitor cells (capable of adipogenic and osteogenic differenti-
ation) was described [46]. Further, endothelial progenitor cells
(CD34+CD133+Flk-1+) were identified in neointima of proximal
thromboembolic material as well as distal regions (downstream of
the thromboembolic material) [47]. Myofibroblast-like cells were
described as hyperproliferative, anchorage-independent, invasive
and serum-independent [48]. These myofibroblast-like cells were
later termed sarcoma-like cells as the injection into the tail veins of
C.B-17/lcr-scid/scidJcl mice led to the development of tumors
growing along the intimal surface of the pulmonary vessels (a
mouse model for pulmonary artery intimal sarcoma) [49]. A
possible functional role of RAGE and HMGB1 in myofibroblasts
of remodeled PA vessels in patients with CTEPH may be inferred
from recent studies describing a role for RAGE in iPAH. In
PASMCs of patients with PAH, RAGE was 6-fold upregulated,
induced STAT3 activation and decreased the expression of
BMPR2 and PPARc. The described cell phenotype could be
induced by RAGE agonist 100A4 in control PASMCs and
reversed by RAGE blockade with RAGE small interfering RNA
(siRNA) in both cell types. RAGE blockade reduced PA pressures
and right ventricular remodeling associated with improved lung
perfusion and vascular remodeling in in vivo animal models of
monocrotaline- and Sugen-induced PAH. Immunofluorescence
staining revealed a correlation of RAGE protein expression with
disease severity in patients with PAH [42]. Disease severity was
classified as mild, moderate and severe. As increased sRAGE
concentrations in our study did not correlate with PAPmean, we
chose to investigate RAGE expression in prototypical vessel
changes according to the modified Heath and Edwards classifi-
cation that was routinely applied during the diagnostic workup of
lungs with iPAH at our institution. We found a greater staining
intensity in endothelial cells as well as smooth muscle cells of
higher Heath Edwards grades.
Recently, a role of the damage-associated molecular pattern
molecule (DAMP) HMGB1 was shown to contribute to PH via a
TLR4-dependent mechanism in a mouse model of CH-induced
PH. In patients with iPAH extra-nuclear HMGB1 in pulmonary
vascular lesions was identified. Increased concentrations of serum
HMGB1 correlated with PAPmean. In C57BL6/J mice exposed to
CH-induced PH a statistically not significant nearly two-fold
increase in RAGE mRNA was observed. Also of interest are the
observations in RAGE knockout (RAGE2/2) compared to wild-
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type mice exposed to CH: there was the same increase in right
ventricular (RV) systolic pressure, but decreased RV hypertrophy
in RAGE2/2 mice. In the same model RAGE2/2 mice neither
showed significantly different vascular changes nor did the levels of
mouse endothelin 21 (ET-1) or mouse soluble intracellular
adhesion molecule 1 (sICAM-1) differ [43]. Our data on human
patients support a role of the RAGE axis, namely RAGE and
HMGB1, in iPAH. The lack of significant differences in
pulmonary vascular changes and circulating cytokines in
RAGE2/2 mice is puzzling and does not parallel our data –
stronger expression of RAGE in higher Heath Edwards stages - or
the above described data by Meloche et al - 6-fold upregulation of
RAGE in PASMCs of patients with PAH [42]. With the current
limited evidence we can only attribute the differences between
mice and men to intrinsic mechanisms of the mouse model of CH-
induced PH.
The migration of human pulmonary artery endothelial cells
(huPAEC) in vitro could be inhibited by HMGB1 via TLR4 and
IRF3-dependent mechanisms [50]. If this HMGB1 effect can also
be reversed by blockade of RAGE still has to be tested. In our
study we demonstrated RAGE expression in endothelial cells of
large and small (,500 mm) regular PAs, neointima of proximal
remodeled PAs and recanalizing vessel-like structures of distal
endarterectomised tissue of patients with CTEPH, as well as
prototypical Heath Edwards lesions in patients with PH.
Endothelial RAGE was present in health and disease. The
behavior of endothelial cells from diseased and healthy tissues
could reveal further information.
In patients with chronic heart failure and impaired left
ventricular function activation of the immune system as measured
by increased levels of proinflammatory cytokines is associated with
poor prognosis [51,52]. No differences in serum concentrations of
the measured cytokines: TNF-alpha, its soluble receptors 1 and 2
(sTNFR1 and 2), IL-10, high sensitivity C-reactive protein
(hsCRP) and N-terminal-pro-B-type natriuretic peptide (NT-
proBNP was measured in plasma) were found when right
ventricular dysfunction due to CTEPH and left ventricular
dysfunction due to chronic heart failure were compared [51]. In
order to help untangle the possible sources by which sRAGE
serum concentrations increased in patients with CTEPH and
iPAH we compared serum measurements in patients with CTEPH
before and after PEA and in patients with iPAH before and after
lung transplantation to those of patients with AVS before and after
AVR. In this experiment right ventricular remodeling with
pressure overload resulting from pulmonary vascular disease
(CTEPH and iPAH) is compared to left ventricular remodeling
as a consequence of the pressure-overloaded left ventricle observed
in patients with aortic stenosis. The results of our experiment point
to a pulmonary source of sRAGE as there was no elevation in
serum of patients with AVS. A normalization of sRAGE in serum
after PEA or lung transplantation can probably not be expected
regarding the neurohumoral and immunological disturbances
occurring in these patients [10]. Possible pitfalls of our model are
two emerging conceptual differences between right and left
ventricular adaptation and remodeling: (1) right ventricular
enlargement occurs earlier in the course of PAH when compared
to pressure-overloaded left ventricles, probably because of the
smaller thickness of the right ventricle that will experience greater
wall stress for comparable increases in pressure. And second, there
is much less myocardial fibrosis in patients with RV pressure
overload compared to patients with AVS which explains the high
rate of recovery of right ventricular function after lung transplan-
tation, even when right ventricular ejection fraction was severely
reduced at the time of transplantation [53,54,55]. Regarding these
differences, we cannot exclude the possibility that sRAGE is
derived (in part) from a myocardial source. Concerning the
myocardium, the intra-coronary administration of sRAGE atten-
uated cardiac remodeling and fibrosis in minipigs with ischemia-
reperfusion injury [56].
Our results on patients with AVS are in line with a previous
study that showed that plasma sRAGE levels were significantly
lower in patients with AVS than in controls and independently
associated with the risk for AVS. In that study there was an inverse
correlation with age, cholesterol levels and coronary calcification
[57].
In lung transplant recipients elevated plasma sRAGE concen-
trations measured four hours after reperfusion of the lung allograft
were associated with longer duration of mechanical ventilation
and longer intensive care unit length of stay [58]. Increased
plasma levels of sRAGE were associated with primary graft
dysfunction at six and 24 hours after lung transplantation [59].
Elevated plasma sRAGE measured 24 hours postoperatively was
associated with the development of bronchiolitis obliterans
syndrome [60]. No data exist on RAGE and lung transplantation
for iPAH. In our study there was a non-significant reduction in
serum sRAGE concentrations in stable lung transplant recipients 3
weeks post transplantation.
Multivariate logistic regression analysis revealed plasma sRAGE
concentrations immediately after cardiopulmonary bypass surgery
to be an independent predictor for postoperative acute lung injury
after cardiac surgery in children [61]. Similarly, S100A12 and
sRAGE were associated with increased length of hospitalization
after non-urgent coronary artery bypass grafting surgery [62]. The
comparison of early (ten days) and late (one year) sRAGE
measurement in our study did not show significant differences
which infers that the high serum concentrations also after surgery
may not only be influenced by the trauma of the surgical
intervention alone but also by disease specific alterations in the
RAGE axis that may not be influenced by current treatment
modalities.
Current standard preoperative evaluation of PEA candidates is
unreliable in predicting patients at risk for persistent pulmonary
hypertension because of surgically inaccessible thromboembolic
material or coexistent small vessel disease which are major reasons
for poor outcome [63]. Attempts to identify high risk patients are
currently investigated. In a recent study, the preoperative
assessment of upstream resistance correlated with postoperative
pulmonary resistance index and PAPmean [64]. In our study,
preoperative sRAGE serum concentrations were significantly
higher in patients with iPAH compared to CTEPH and did not
correlate with the height of pulmonary artery pressures. This could
have implications on the decision to perform pulmonary
endarterectomy on patients with CTEPH. The question that has
to be answered in future studies is: can high serum concentrations
of sRAGE, such as measured in iPAH in this study, unmask distal
disease that is not accessible to PEA and thus be of value in
preoperative decision making regarding operability of CTEPH
patients with high pulmonary vascular resistance (PVR.1200
dynes.cm/s5) [65]?
As sRAGE serum concentrations did not correlate with their
corresponding pulmonary artery pressures in this study we can
only hypothesize about an on/off-phenomenon of chronic
inflammation in iPAH and CTEPH patients. The current
information raises new questions. What pathophysiologic thresh-
old has to be reached to turn on chronic inflammation through the
RAGE axis? Is the RAGE axis involved in the primary events of
remodeling of the thromboembolic material into the PA vessel wall
or is it turned on at later stages of CTEPH and iPAH? Could
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RAGE blockade terminate chronic inflammation in these diseases
and be of clinical value in patients as an adjunct to current
therapies?
We are not suggesting that our absolute concentration values
can be used to make any judgments about the diagnosis of, for
example CTEPH. While comparative results (e.g. control vs.
CTEPH) gained during one experiment could be repeated in
separate ELISA experiments, the absolute values for the individual
serum samples vary in our experienced hands with the recom-
mended additional reagents from the manufacturer. So we never
compare absolute values from samples measured with the RAGE
Duoset from different experiments. The intraassay coefficient of
variation was 2.3%. We run control serum samples on each
ELISA. The RAGE Duoset has quite some interassay variability.
The commercially available ELISA is sold for research use only
and not for diagnostic purposes. We don’t see this interassay
variability with the other ELISA assays used in this manuscript.
Soluble RAGE was measured in serum/plasma of other
pulmonary diseases with different methods. In stable COPD
patients plasma sRAGE was significantly lower compared to
healthy control subjects: 400.2 pg/ml vs. 783.3 pg/ml, p,0.001;
measured by ELISA, R&D systems, Minneapolis, MN, USA [66].
Another study used two different multiplex platforms (Luminex
multi-analyte profiling at Rules Based Medicine, RBM, Austin,
TX and Searchlight at Aushon Biosystems, Bellaria, MA) to find
significant differences in serum sRAGE concentrations in non-
smokers, smokers, COPD I/II and COPD III/IV: median
sRAGE values [ng/ml] 4.2, 3.2, 2.7 and 2.2, p = 0.003 [67]. A
study using Quanitkine human RAGE ELISA kit (R&D systems,
Minneapolis, MN, USA) found significantly different lower
sRAGE concentrations in patients with COPD compared to
smoking and nonsmoking controls subjects: sRAGE values [pg/
ml]: 1351.1 vs. 1736.6 and 1797.3, p,0.001 [68]. There are 2.8-
to 10.5-fold differences between the controls or COPD patients
when the three studies with different analytical methods and
different population samples are compared. Regarding the
different absolute concentrations reported for sRAGE as exem-
plified with three studies for COPD as another pulmonary disease,
it is too vague for us to draw conclusions from the comparison of
absolute sRAGE measurements between our and other studies.
In summary, we have shown the expression of RAGE and
HMGB1 in myofibroblasts of endarterectomised tissues from
patients with CTEPH and increased expression of RAGE in
prototypical lesions in lung of patients with iPAH. Our immuno-
histochemical results were corroborated by alterations in the
serum concentration of soluble RAGE variants and HMGB1. The
results may have substantial implications for diagnosis and/or
treatment of patients with pulmonary hypertension. PEA improves
the local control of disease with the resultant decrease in
pulmonary artery pressure but may not influence the systemic
inflammatory mechanisms in CTEPH patients through the RAGE
pathway. A more detailed understanding of the RAGE-HMGB1
axis and related molecules in diseases associated with pulmonary
hypertension is needed and warrants future study.
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